<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02343094</url>
  </required_header>
  <id_info>
    <org_study_id>2013-003924-35</org_study_id>
    <nct_id>NCT02343094</nct_id>
  </id_info>
  <brief_title>Phenylbutyrate in Proteinuric Nephropathies</brief_title>
  <acronym>PIRATE</acronym>
  <official_title>Phenylbutyrate Effect on Lcn2 Urianry Expression in Proteinuric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether sodium phenylbutyrate can reduce Lcn2
      urinary expression in proteinuric patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proteinuria is a major prognosis factor of chronic kidney disease (CKD) progression.
      Convergent evidences from clinical and experimental studies indicate that albuminuria and
      proteinuria are not simply a marker of CKD progression, but an active player in the evolution
      of the disease. Mechanistically, it has been shown that proteinuria induces endoplasmic
      reticulum stress in tubular cells, leading to induction of lipocalin 2/NGAL, a critical
      element of CKD progression. Moreover, proteinuric mice treated with phenylbutyrate are
      protected from CKD progression.

      The aim of this study is to evaluate the efficacy of phenybutyrate, a molecular chaperone
      which inhibits ER stress, on the proteinuria-induced NGAL expression. Urinary NGAL/creatinine
      ratio will be evaluated in proteinuric patients before and under treatment with
      phenylbutyrate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Lcn2/creatinine ratio</measure>
    <time_frame>Day 7, Day 15, Day 21, Day 28</time_frame>
    <description>Reduction of 50 % of Lcn2 concentration, measured with ELISA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary protein/creatinine ratio</measure>
    <time_frame>Day 7</time_frame>
    <description>Reduction of 30% of the proteinurie and the albuminuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary protein/creatinine ratio</measure>
    <time_frame>Day 15</time_frame>
    <description>Reduction of 30% of the proteinurie and the albuminuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary protein/creatinine ratio</measure>
    <time_frame>Day 21</time_frame>
    <description>Reduction of 30% of the proteinurie and the albuminuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary protein/creatinine ratio</measure>
    <time_frame>Day 28</time_frame>
    <description>Reduction of 30% of the proteinurie and the albuminuria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Proteinuric Diseases</condition>
  <arm_group>
    <arm_group_label>PBA 7,5g/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBA 15g/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBA 7,5g/d</intervention_name>
    <description>Treatment for 14 days with PBA</description>
    <arm_group_label>PBA 7,5g/d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBA 15g/d</intervention_name>
    <description>Treatment for 14 days with PBA</description>
    <arm_group_label>PBA 15g/d</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic Kidney disease for ore than 3 months

          -  Proteinuria &gt; 1g/d or 0,1g/mmmol creatinine

          -  eGFR &gt;30ml/mn/1,73m2

          -  written informed consent

          -  affiliated with social security health insurance

        Exclusion Criteria:

          -  Women with childbearing potential

          -  Recent (&lt;3 months) modification of ACE inhibitors or ARB

          -  Acute renal failure

          -  eGFR &lt;30ml/mn/1,73m2

          -  Nephrotic syndrome (albuminélia &lt;30g/l)

          -  Infection with HIV, HCV, HBV

          -  Liver insufficiency

          -  No affiliated with social security health insurance

          -  inclusion in another protocol of biomedical research

          -  risk of non-adherence to protocol and visits

          -  patients having a cardiac insufficiency of grade 3 or 4

          -  patient requiring of a strict salt-free diet

          -  patients under corticoids or immunosuppresseurs

          -  clinical intolerance in the treatment

          -  intolerance in the fructose, the syndrome of malabsorption glucose and galactose or a
             deficit in sucrase / isomaltase

          -  patients treated by Probenecide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand KNEBELMANN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Néphrologie Adulte, Hôpital Necker</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2015</study_first_submitted>
  <study_first_submitted_qc>January 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2015</study_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Proteinuria</keyword>
  <keyword>Lipocalin 2</keyword>
  <keyword>Neutrophil gelatinase associated lipocalin</keyword>
  <keyword>ELISA</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4-phenylbutyric acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

